Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBIT (2023 - 2026)

Camp4 Therapeutics' EBIT history spans 3 years, with the latest figure at -$12.8 million for Q4 2025.

  • On a quarterly basis, EBIT rose 8.96% to -$12.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$52.6 million, a 1.0% increase, with the full-year FY2025 number at -$52.6 million, up 1.0% from a year prior.
  • EBIT hit -$12.8 million in Q4 2025 for Camp4 Therapeutics, up from -$13.7 million in the prior quarter.
  • Over the last five years, EBIT for CAMP hit a ceiling of -$12.3 million in Q3 2023 and a floor of -$14.0 million in Q4 2024.
  • Historically, EBIT has averaged -$13.1 million across 3 years, with a median of -$13.1 million in 2025.
  • Biggest five-year swings in EBIT: fell 9.55% in 2024 and later grew 8.96% in 2025.
  • Tracing CAMP's EBIT over 3 years: stood at -$13.5 million in 2023, then dropped by 4.14% to -$14.0 million in 2024, then grew by 8.96% to -$12.8 million in 2025.
  • Business Quant data shows EBIT for CAMP at -$12.8 million in Q4 2025, -$13.7 million in Q3 2025, and -$13.0 million in Q2 2025.